Literature DB >> 29018973

Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch-Schonlein purpura in children.

Xu Teng1, Cuiyun Gao2, Mei Sun1, Jie Wu3.   

Abstract

The objective of this study is to explore the value of fecal calprotectin (FC) for early screening of the abdominal type of Henoch-Schonlein purpura (AHSP) in children. The study cohort included 40 children with AHSP treated at Shengjing Hospital of China Medical University from November 2014 to November 2015, and 40 children hospitalized in the Division of Pediatric Orthopedics in the corresponding period were selected as a control group. Fresh fecal samples were collected in the acute phase of the first visit (FC1), 3 days after treatment (FC2), and 7 days after treatment (FC3) from the AHSP group and the control group. Calprotectin levels in the fecal samples were measured using an enzyme-linked immunosorbent assay. At the same time, gastrointestinal performance and the laboratory examination indicators white blood cell (WBC) count and C-reactive protein (CRP) level were recorded. The median levels of FC1 (3053 μg/g) and FC2 (2778.3 μg/g) were higher than in the control group (102.5 μg/g), with significant differences among the three groups (p < 0.001). FC levels gradually decreased in remission, and the level of FC3 on day 7 was close to that of the control samples (p > 0.05). When the optimal cut-off was 264.5 μg/g, the area under the receiver operating characteristic (ROC) curve of FC for diagnosis of AHSP was 0.961 with a corresponding sensitivity and specificity of 93.1 and 87.5%, respectively. The levels of FC in children with AHSP were positively correlated with WBC count (r s = 0.688) and CRP value (r s = 0.513). The area under the ROC curve of WBC count for screening AHSP was 0.785 when the optimal cut-off value was 11.1 × 109/L with a corresponding sensitivity and specificity of 81.5 and 62.5%, respectively. The area under the ROC curve of CRP was 0.963 when the optimal cut-off value was 5.72 mg/dL with a corresponding sensitivity and specificity of 88.9 and 100%, respectively. Comparisons of FC, WBC count, and CRP level as diagnostic indicators of AHSP showed that the sensitivity of FC was higher than that of the WBC count and CRP level, and its diagnostic value was better than that of the WBC count. The levels of FC began to increase in the early stages of AHSP, showing a decreasing tendency in remission and tending to be within a normal range after a week or so. For the early diagnosis of AHSP, FC with a cut-off level of 264.5 μg/g has good sensitivity and specificity. The sensitivity of FC is better than that of the traditional inflammation indicators CRP and WBC count, and its diagnostic performance is better than WBC count; FC can be suitable as a new marker for the early diagnosis of AHSP.

Entities:  

Keywords:  Diagnosis; Fecal calprotectin; Gastrointestinal symptoms; Henoch–Schonlein purpura

Mesh:

Substances:

Year:  2017        PMID: 29018973     DOI: 10.1007/s10067-017-3864-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  32 in total

1.  A fermented formula in pre-term infants: clinical tolerance, gut microbiota, down-regulation of faecal calprotectin and up-regulation of faecal secretory IgA.

Authors:  Florence Campeotto; Antonia Suau; Nathalie Kapel; Fabien Magne; Vivian Viallon; Laurent Ferraris; Anne-Judith Waligora-Dupriet; Pascale Soulaines; Bernard Leroux; Nicolas Kalach; Christophe Dupont; Marie-José Butel
Journal:  Br J Nutr       Date:  2011-03-22       Impact factor: 3.718

Review 2.  Fecal calprotectin in systemic sclerosis and review of the literature.

Authors:  I Marie; A-M Leroi; J-F Menard; H Levesque; M Quillard; P Ducrotte
Journal:  Autoimmun Rev       Date:  2015-02-04       Impact factor: 9.754

Review 3.  Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.

Authors:  Anke Heida; K T Park; Patrick F van Rheenen
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

4.  The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.

Authors:  Lukasz Kwapisz; Jamie Gregor; Nilesh Chande; Brian Yan; Terry Ponich; Mahmoud Mosli
Journal:  Scand J Gastroenterol       Date:  2017-04-20       Impact factor: 2.423

5.  Henoch-Schönlein purpura complicated with severe gastrointestinal bleeding.

Authors:  Tomoyuki Yamazaki; Tetsu Akimoto; Yoshitaka Iwazu; Taro Sugase; Eri Takeshima; Akihiko Numata; Takanori Komada; Hiromichi Yoshizawa; Naoko Otani; Yoshiyuki Morishita; Osamu Saito; Fumi Takemoto; Shigeaki Muto; Eiji Kusano; Daisuke Nagata
Journal:  CEN Case Rep       Date:  2014-10-02

6.  Faecal calprotectin concentrations in children with functional gastrointestinal disorders diagnosed according to the Pediatric Rome III criteria.

Authors:  G Flagstad; H Helgeland; T Markestad
Journal:  Acta Paediatr       Date:  2010-03-05       Impact factor: 2.299

7.  Fecal calprotectin levels in healthy children studied with an improved assay.

Authors:  Ulrika Lorentzon Fagerberg; Lars Lööf; Rumjana Djilali Merzoug; Lars-Olof Hansson; Yigael Finkel
Journal:  J Pediatr Gastroenterol Nutr       Date:  2003-10       Impact factor: 2.839

8.  A five year review of clinical profile in HSP.

Authors:  N Grover; N Sankhyan; J P Bisht
Journal:  JNMA J Nepal Med Assoc       Date:  2007 Apr-Jun       Impact factor: 0.406

9.  Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease.

Authors:  Steven T Leach; Zheng Yang; Isabella Messina; Changjie Song; Carolyn L Geczy; Anne M Cunningham; Andrew S Day
Journal:  Scand J Gastroenterol       Date:  2007-11       Impact factor: 2.423

Review 10.  Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.

Authors:  Patrick F van Rheenen; Els Van de Vijver; Vaclav Fidler
Journal:  BMJ       Date:  2010-07-15
View more
  4 in total

1.  Clinical outcome in pediatric refractory gastrointestinal Henoch-Schönlein purpura treated with mycophenolate mofetil.

Authors:  Haiyan Wang; Bihong Zhang; Sha Li; Rongqiong Ou; Yong Liu; Weiping Tan
Journal:  Eur J Pediatr       Date:  2020-03-06       Impact factor: 3.183

2.  Late Relapse of Henoch-Schönlein Purpura in an Adolescent Presenting as Severe Gastroduodenitis.

Authors:  Chiara Rubino; Monica Paci; Massimo Resti; Paolo Lionetti; Sandra Trapani
Journal:  Front Pediatr       Date:  2018-11-20       Impact factor: 3.418

3.  Case Report: Systemic Small-Vessel Vasculitis in an Adolescent With Active Ulcerative Colitis.

Authors:  Marleen Bouhuys; Wineke Armbrust; Patrick F van Rheenen
Journal:  Front Pediatr       Date:  2021-02-10       Impact factor: 3.418

4.  Fecal calprotectin as a marker of gastrointestinal involvement in pediatric Henoch-Schönlein purpura patients: a retrospective analysis.

Authors:  Eun Young Paek; Dae Yong Yi; Ben Kang; Byung-Ho Choe
Journal:  BMC Pediatr       Date:  2020-08-08       Impact factor: 2.125

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.